Balance Sheet
Accumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HUTCHMED (China) (HCM) Receivables: 2015-2025

Historic Receivables for HUTCHMED (China) (HCM) over the last 1 years, with Jun 2025 value amounting to $168.5 million.

  • HUTCHMED (China)'s Receivables fell 1.84% to $168.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $649.8 million, marking a year-over-year increase of 2.91%. This contributed to the annual value of $151.2 million for FY2022, which is 8.15% down from last year.
  • According to the latest figures from Q2 2025, HUTCHMED (China)'s Receivables is $168.5 million, which was down 1.84% from $171.6 million recorded in Q2 2024.
  • HUTCHMED (China)'s Receivables' 5-year high stood at $171.6 million during Q2 2024, with a 5-year trough of $4.8 million in Q1 2021.
  • For the 3-year period, HUTCHMED (China)'s Receivables averaged around $166.2 million, with its median value being $168.5 million (2025).
  • In the last 5 years, HUTCHMED (China)'s Receivables skyrocketed by 117.18% in 2021 and then fell by 8.15% in 2022.
  • HUTCHMED (China)'s Receivables (Quarterly) stood at $164.6 million in 2021, then fell by 8.15% to $151.2 million in 2022, then grew by 5.58% to $158.5 million in 2023, then climbed by 8.30% to $171.6 million in 2024, then declined by 1.84% to $168.5 million in 2025.
  • Its Receivables was $168.5 million in Q2 2025, compared to $171.6 million in Q2 2024 and $158.5 million in Q2 2023.